Cargando…
Novel Therapies in Platinum-refractory Metastatic Germ Cell Tumor: A Case Report with a Focus on a PD-1 Inhibitor
Testicular germ cell tumor (GCT) is the most common malignancy in young males between the ages of 15 to 35 years. Although the overall cure rate of GCTs approaches 95%, almost 25% of patients with distant metastases die from the cancer. Active investigations on novel treatment options for platinum-r...
Autores principales: | Loh, Kah Poh, Fung, Chunkit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PAGEPress Publications, Pavia, Italy
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617913/ https://www.ncbi.nlm.nih.gov/pubmed/28975019 http://dx.doi.org/10.4081/rt.2017.6867 |
Ejemplares similares
-
Chemotherapy refractory testicular germ cell tumor is associated with a variant in Armadillo Repeat gene deleted in Velco-Cardio-Facial syndrome (ARVCF)
por: Fung, Chunkit, et al.
Publicado: (2012) -
Immunotherapy with PD-1 Inhibitor Nivolumab in Recurrent/Metastatic Platinum Refractory Head and Neck Cancers—Early Experiences from Romania and Literature Review
por: Mireștean, Camil Ciprian, et al.
Publicado: (2023) -
A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer
por: Albany, Costantine, et al.
Publicado: (2020) -
Clonal analyses of refractory testicular germ cell tumors
por: Barrett, Michael T., et al.
Publicado: (2019) -
Hematopoietic stem cell mobilization strategies to support high-dose chemotherapy: A focus on relapsed/refractory germ cell tumors
por: Porfyriou, Eleni, et al.
Publicado: (2021)